Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXOPHYLLIN vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
500 mg orally once daily with a full glass of water, regardless of meals.
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Approximately 40-60% bound to plasma proteins, primarily albumin. Binding is saturable and may decrease in uremia or with elevated bilirubin. In neonates, protein binding is lower (about 20-30%) due to decreased albumin concentrations.
98% bound to albumin and alpha-1-acid glycoprotein.
Volume of distribution: approximately 0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Theophylline distributes into total body water, with some accumulation in tissues. Vd is increased in neonates (0.6-0.9 L/kg) and decreased in obesity (0.3-0.4 L/kg adjusted for ideal body weight).
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral immediate-release: 90-100% (well absorbed). Oral extended-release: 80-100% (inter- and intra-subject variability exists). Rectal solution: 80-90%. Rectal suppository: 60-70% (erratic absorption). Intravenous: 100%.
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
Theophylline pharmacokinetics are not significantly altered in renal impairment. No dose adjustment recommended for GFR >15 m L/min. For end-stage renal disease (GFR <15 m L/min), monitor serum theophylline concentrations closely as clearance may be reduced; consider 25% dose reduction and follow levels.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh Class A: Reduce dose by 50% of usual. Child-Pugh Class B: Reduce dose by 50-75% of usual. Child-Pugh Class C: Contraindicated or reduce dose by 80% with close monitoring. Serum theophylline concentration monitoring is mandatory.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Immediate-release: Initial dose 16 mg/kg/day or 400 mg/day (whichever is less) PO divided every 6-8 hours; titrate based on serum theophylline concentration. Typical maintenance: <1 year: 0.2 x age in weeks + 5 mg/kg/day; 1-9 years: 24 mg/kg/day; >9 years: 16 mg/kg/day. Maximum dose 800 mg/day.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Elderly patients (>60 years) have reduced theophylline clearance. Initial dose 300 mg/day PO divided every 8-12 hours; maximum recommended dose 400 mg/day. Monitor serum theophylline concentrations closely and adjust to avoid levels >15 mcg/m L due to increased risk of toxicity.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
No FDA black box warning.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with levels >20 mcg/m L. Use caution in patients with cardiac disorders, hepatic impairment, elderly, and those on medications that alter theophylline metabolism.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to theophylline or any component of the formulation; peptic ulcer disease; seizure disorder (unless adequately controlled).
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid high-caffeine foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. Dietary protein and charcoal-broiled meats may increase clearance, potentially reducing efficacy. Consistency in diet is recommended.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limited; may be associated with intrauterine growth restriction and neonatal withdrawal if used near term. Second trimester: Risk of tachyarrhythmias and fetal hypoxia due to maternal toxicity. Third trimester: Increased risk of neonatal apnea, jitteriness, and irritability due to transplacental passage. Avoid use unless clearly needed.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Peak milk levels occur 2-4 hours after dose. Infant serum levels are typically low (10-30% of maternal levels). Risk of irritability and jitteriness in infants. Use with caution; monitor infant for adverse effects.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
Due to increased clearance of theophylline in pregnancy (by up to 30-50%), dose adjustments are often required. The half-life may decrease significantly, especially in the second and third trimesters. Consider starting with higher doses or more frequent intervals (e.g., every 6-8 hours). Monitor serum concentrations every 2-4 weeks and adjust to maintain therapeutic levels. Postpartum, clearance may decrease, requiring dose reduction.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
ELIXOPHYLLIN is a brand name for theophylline elixir. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or COPD. Adjust dose based on smoking status (smokers require higher doses). Drug interactions: cimetidine, ciprofloxacin, fluvoxamine increase levels; phenytoin, carbamazepine, rifampin decrease levels.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, diarrhea, headache, insomnia, irritability, rapid heartbeat, or seizures.,Do not crush or chew extended-release tablets; take elixir with a measuring device for accurate dose.,Notify your doctor if you start or stop smoking, as tobacco use affects how this drug works.,Store at room temperature away from moisture and heat.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXOPHYLLIN vs ELIXOMIN, answered by our medical review team.
ELIXOPHYLLIN is a Xanthine Bronchodilator that works by Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXOPHYLLIN and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXOPHYLLIN is: Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXOPHYLLIN and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXOPHYLLIN is classified as Category C. Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limite. ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.